AGMATINE, THE PRODUCT OF L-arginine decarboxylation by arginine decarboxylase, plays an important role as a regulatory component of the polyamine pathway ( Fig. 1) (14, 27) . At least in part, this is related to its structural similarity to polyamines such as putrescine (27) . In particular, agmatine leads to a reduction of ornithine decarboxylase activity (12, 25) and to an inhibition of polyamine uptake (15, 25, 26) . Recently, evidence was presented that an increase in intracellular agmatine concentration is associated with a decrease in neoplastic cell expansion (18) . This view is supported by several observations: 1) it has been demonstrated that agmatine, despite its similarity in structure to polyamines, fails to substitute functionally for polyamines in cell proliferation (12, 27) . 2) RNA interference targeting arginine decarboxylase resulted in a significant increase in proliferation of the human intestinal tumor cell line SW480, which was paralleled by a distinct decrease of intracellular agmatine content (14) . 3) Vice versa addition of arginine decarboxylase to the culture medium of HeLa cells caused arrest of the cell growth (22) . Hence, the regulatory mechanisms underlying intracellular agmatine homeostasis are of high physiological and pathophysiological relevance; they are subject of the present investigation.
For ethical reasons, it is not possible to directly study such mechanisms in humans. However, indirect information not only on pathophysiological, but also on physiological mechanisms, is provided, e.g., by the availability of tissue specimens from surgical therapy of colon cancer, by in vitro analysis of agmatine formation by intestinal bacteria strains, and by determination of parameters that can normally not be measured but become accessible within a complex technique established for necessary therapeutic procedures in liver cirrhosis.
In more detail, human colon cancer tissue was used as an experimental model for tissues with impaired agmatine homeostasis (18) . As the first aim, we examined the role of agmatine-synthesizing and -metabolizing enzymes as regulatory factors by determining whether neoplastic colon cancer tissue and the adjacent macroscopically normal tissue differ in the expression of the enzymes arginine decarboxylase (catalyzing the reaction from L-arginine to agmatine), diamine oxidase (catalyzing the degradation of agmatine to 4-guanidinobutyrate), agmatinase (catalyzing the reaction from agmatine to putrescine), and ornithine decarboxylase (catalyzing the reaction from ornithine to putrescine; Fig. 1 ).
Absorption of bacterial agmatine from the gut lumen is another factor that essentially influences agmatine homeostasis in the mammalian organism (17) . Therefore, the second aim of the present study was to compare ten representative intestinal bacterial species with respect to agmatine production and its efflux into the culture medium.
In rat about 60% of agmatine taken up from the stomach and intestine is accumulated in the liver (16) and undergoes enterohepatic circulation. In rat hepatocyte cultures, 50% of agmatine taken up by the cells are transformed to 4-guanidinobutyraldehyde and 10% to polyamines; only 30% are recovered as nonmetabolized agmatine (1) . On the other hand, hepatocytes themselves are also capable of synthesizing agmatine (7) . Thus the liver appears to play a crucial role in the regulation of the agmatine concentration in the systemic circulation. Data concerning the predominance of biosynthesis or removal of agmatine, i.e., its gain or loss during passage of the blood through the human liver, are not available. In the third part of the study, we therefore analyzed the concentration of agmatine in blood samples drawn simultaneously from the portal and hepatic vein of patients with liver cirrhosis during the therapeutic implantation of an intrahepatic portosystemic stent shunt. To our knowledge, this is the first report on blood agmatine concentrations in samples taken simultaneously from the portal and hepatic vein in humans.
MATERIALS AND METHODS

RT-PCR.
All patients gave their informed consent to the investigation of their resectates, which were obtained during colon cancer surgery. The study was approved by the Ethics Committee at the Faculty of Medicine of the University of Bonn. Total RNA was isolated from the human colon specimens using the RNeasy Mini Kit (Qiagen, Hilden, Germany) with DNase treatment according to the manufacturer's instructions. Total RNA of each sample was reverse transcribed according to the manufacturer's instructions (RevertAid cDNA Synthesis Kit; Fermentas, St. Leon-Rot, Germany; using random hexamer primers). For quantitative RT-PCR, 35 l of amplification mixture (Quantitect SyBrGreen Kit, Qiagen) was used, containing 20 ng of reverse-transcribed RNA and 300 nM of the respective primers (arginine decarboxylase, accession no. NM_052998, forward primer: 5Ј-CTGCCGCAACTACACGTAG-3Ј, reverse primer: 5Ј-GGACATGGCATAGGTGATGTG-3Ј; ornithine decarboxylase, accession no. NM_002539, forward primer: 5Ј-GTGGGTGATTGGATGCTCTTTG-3Ј, reverse primer: 5Ј-AGGCCCTGACATCACATAGTAG-3Ј; agmatinase, accession no. NM_024758, forward primer: 5Ј-CAGCTGGCTGTATTC-CTCTG-3Ј, reverse primer: 5Ј-TATCTGTAGGGATCCAAGGTCG-3Ј; diamine oxidase, accession no. NM_001091, forward primer: 5Ј-GTCCTGAACGTGCACTTCG-3Ј, reverse primer: 5Ј-GCTAACTCAT-GAGTGACGCTG-3Ј) according to the manufacturer's instructions. Reactions (triplicates, 10 l) were run on a Mx3000 real-time cycler (Stratagene, La Jolla, CA). The cycling conditions were 15 s polymerase activation at 95°C and 45 cycles at 95°C for 15 s, at 58°C for 30 s and at 72°C for 30 s. Each assay included a standard curve (5 points from 100 to 0.01 ng/35 l) and no-template controls. The results were analyzed using the Stratagene software (version Mx3000 Pro). The relative mRNA expression (R) was calculated from the ratio of "neoplastic tissue" over "normal tissue", R ϭ E Ct control -cancer (target)/E Ct control -cancer (housekeeper) with the efficiency E ϭ 10 Ϫ1/slope measured with a standard curve in all experiments (21) . The results for the housekeeping gene ␤-actin were determined by the same method (␤-actin forward primer: 5Ј-TCCATCATGAAGTGTGACGT-3Ј; reverse primer: 5Ј-GAGCAAT-GATCTTGATCTTCAT-3Ј). The housekeeping gene stably expressed in all samples was used as an internal standard to normalize mRNA expression, which compensates for differences in sample concentrations and reverse transcription efficiencies. However, in the present experiments, no significant differences were detected comparing normalization to ␤-actin and to total RNA amount showing negligible variations in reverse transcription and PCR efficiencies. The identity of the PCR products was initially confirmed by agarose gel electrophoresis followed by dideoxy chain termination sequencing and then, after each real-time reaction, by melt-point analysis. Although the enzymes would be detected directly as proteins by Western blotting, this approach was not used because of the lack of commercially available antibodies against arginine decarboxylase or diamine oxidase. The expression of mRNA of the respective enzymes was compared with that found in the adjacent macroscopically normal tissue of the same patient.
To investigate the total sequence of the cDNA encoding arginine decarboxylase in neoplastic and adjacent normal tissue, specific PCR primers were designed to amplify the complete coding sequence of arginine decarboxylase. The primer sequences (forward: 5Ј-CG-GAGTTTGTGTGTTGCATAC-3Ј; reverse: 5Ј-ACAGGGCAGAAA-CACTGCAG-3Ј) were adopted from the human arginine decarboxylase reference sequence (accession number NM_052998). RT-PCR was carried out using cDNA and Pfu-Polymerase (Stratagene). The PCR conditions were 30 s polymerase activation at 95°C and 40 cycles of 30 s denaturation at 94°C, 30 s at the annealing temperature of the primers (58°C), and 2-min extension at 72°C, followed by a final extension period at 72°C for 10 min. PCR products were separated by gel electrophoresis on a 0.8% agarose gel. The bands of interest were cut off the gel, and the cDNA was extracted from the gel using the MinElute Gel Extraction Kit (Qiagen). PCR products were then directly sequenced at MWG Biotech (Ebersberg, Germany).
Test bacteria and culture conditions. The human gastrointestinal tract harbors about 400 -600 bacterial species (10) . For any given individual, however, 30 to 40 bacterial species contribute for 99% of the fecal microflora (for review, see Ref. 4) . The intestinal microbiota is dominated by obligate anaerobes (99%). The predominant species of obligate anaerobes belong to the genera Bacteroides (65%), Bifidobacterium (32%), Eubacterium (3%), and Veillonella (0.3%) species. The predominant aerobe and facultative anaerobe microbiota (1%) comprises Escherichia coli (E. coli) (up to 45%), other Enterobacteriaceae (1%), and Enterococcus (up to 45%), or Lactobacillus (9%) species. As typical representatives of the physiological intestinal microflora (19) , the following reference strains were investigated: E. coli and E. faecalis from their lyophilisate on Columbia agar with 5% sheep blood (Becton Dickinson, Heidelberg, Germany) and incubation in normal air of 36°C, test tubes containing 10 ml of brain heart infusion broth (BHI; Oxoid, Wesel, Germany) were inoculated with colony material of three single colonies. The other test strains were propagated in parallel on Columbia agar with 5% sheep blood and on Schaedler agar and incubated under anaerobic conditions (36°C, 72 h) using the GasPak (R) system (Becton Dickinson). Depending on the strength of growth, up to 20 colonies of each strain were transferred into test tubes containing 10 ml of BHI. After anaerobic incubation for 72 h at 36°C, broth cultures were centrifuged for 10 min at 4°C and 6,000 g. Each bacterial strain was harvested during the late log/beginning stationary phase of growth with a yield of bacterial cells in the range of ϳ1,000,000,000 colony forming units/ml before the centrifugation step. Pellets and supernatants and another tube with the original broth cultures were immediately stored in an ice water bath. Due to differences in the cellular bacterial protein content between the various strains, the absolute amount of bacterial protein in the culture dishes differed between the various bacterial strains (Table 1 , right column). Therefore, agmatine content in the pellets and culture media was normalized to the amount of bacterial protein (mg protein, Table 1 ). The absolute amount of bacterial protein in the culture dishes did not correlate with agmatine content in the pellet or culture medium (Table 1, 
right column).
Patients with liver cirrhosis. After obtaining informed consent and approval by the Ethics Committee at the Faculty of Medicine of the University of Bonn, samples of portal and hepatic venous blood plasma were obtained after an overnight fast from 30 patients suffering from liver cirrhosis (age: median 57.5 years, range 41-76, 17 men, 13 women) during the therapeutic implantation of a portosystemic stent shunt. Cirrhosis was due to alcohol or hepatitis C or a combination of both. Child-Pugh score was determined according to Pugh's modification of the original score (23) . All patients had esophageal varices. Samples were obtained from portal venous blood immediately after transhepatic puncture of a portal branch and before insertion of a transjugular intrahepatic portosystemic stent shunt. These samples were compared with samples taken at the same time from the orifice of the hepatic veins. None of the patients received any diuretic or vasoactive medication. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Agmatine determination. Protein was precipitated in the blood plasma samples as well as in the supernatants and pellet homogenisates of the bacterial cultures by addition of 0.6 M perchloric acid and 0.1 M hydrochloric acid in methanol (1:1:0.5, vol/vol/vol). After incubation for 15 min at 4°C, each sample was centrifuged for 5 min at 6,000 g, and agmatine in the supernatant was determined by HPLC as described previously (18) . The detection limit was about 400 pM. The recovery was about 70%. Day-to-day variation of the peak height of the agmatine standard amounted to 5-17%; the reproducibility, i.e., the deviation of the peak height of the same sample measured twice, amounted to less than 2%.
Statistics. Unless stated otherwise, means Ϯ SE are given. Log2 values were calculated for the relative expression of the enzymes (⌬Ct) determined in the quantitative RT-PCR. Since these log values were distributed normally, the t-test for unpaired data was used to analyze whether expression of the enzymes in the tumor tissue significantly differed from that in the adjacent normal tissue.
Since the agmatine values did not follow a Gaussian distribution, nonparametric Spearman correlation analysis of agmatine levels in portal and hepatic venous blood plasma of the individual patients was performed. In six portal venous blood samples plasma agmatine concentrations were above 14 ng/ml, i.e., they were outside of the mean plus four times standard deviation of agmatine concentration of the 24 other patients, which identified them as belonging to a subgroup. Comparison of these six values with agmatine concentration in the portal venous blood samples of the residual 24 patients (all below 10 ng/ml) by the Mann-Whitney-test significantly (P ϭ 0.0024) indicated that the two groups of samples do not belong to the same main unit.
RESULTS
Human colon tissue.
Resectates from 10 patients (5 women, 5 men; median age 71 yr, range 60 -92 yr) with colon carcinoma who underwent surgery were investigated. Expression of mRNA encoding arginine decarboxylase and diamine oxidase in neoplastic tissue specimens was decreased to about onefourth and one-half, respectively, of that found in the adjacent macroscopically normal tissue (Fig. 2) . In contrast, expression of mRNA for ornithine decarboxylase was increased about 2.5-fold (Fig. 2) . No significant difference was observed in the expression of agmatinase between neoplastic tissue and adjacent normal tissue (Fig. 2) .
No mutations were detected in cDNAs encoding arginine decarboxylase in neoplastic and adjacent normal tissue when compared with the reference wild-type sequence (analyzed for all resectates, data not shown).
Production of agmatine by selected bacteria and efflux into the culture medium. Most of the bacteria investigated (exceptions: Eggerthella lenta and Enterococcus faecalis, see below) are capable of producing considerable amounts of agmatine. Applicable values are means Ϯ SE of duplicate determinations from n (in parentheses) cultures. 1 (agmatine released into the culture medium)/(agmatine released into the culture medium ϩ residual agmatine content in the bacteria) ϫ 100. 2 Mean values of bacterial protein in cultures grown at the same time for 72 h.
A-G The strains which were included into the statistical analysis have been designated by the letters A-G as indicated in parentheses in the first column. The difference between the mean of the bacterial strain in the respective row and the means of the bacterial strains indicated by the superscripts was statistically different with P Ͻ 0.001 (one-way ANOVA with Bonferroni post test). *Data were not included into the statistical analysis because of n ϭ 1. †Apparent rate of agmatine effux was not calculated because agmatine formation by this bacterial strain was detectable in only 4 of 6 culture dishes. ‡This bacterial strain was cultured in a separate series. §Apparent rate of agmatine effux was not calculated because agmatine formation by this bacterial strain was detectable in only 2 of 6 culture dishes.
This can be derived from the finding that it is present both in the bacteria themselves and in the culture medium; agmatine in the medium mainly reflects efflux of the compound from the bacteria into the medium but may, to a limited extent, also be due to efflux of agmatine from dead bacterial cells. The culture media of the various strains of bacteria largely differed in their agmatine content. A very high content was determined in the media of Bacteroides vulgatus, Lactobacillus reuteri, Lactobacillus acidophilus, and Veillonella dispar (Table 1 ). In the culture media of Bacteroides fragilis, Bacteroides thetaiotaomicron, Bifidobacterium bifidum, and E. coli Nissle, lower but still reasonably high levels of agmatine content were detected. Eggerthella lenta and Enterococcus faecalis are exceptions in that only almost negligible amounts of agmatine were present in the bacteria, and that agmatine in the culture medium of these bacteria was also much lower (with large variations between the individual values) than in the case of the other bacteria (Table 1) .
For each of the latter strains of bacteria, the apparent rate of agmatine efflux was determined as a measure of the ability of agmatine to flow out of the bacteria into the surrounding medium. The apparent rate of efflux was calculated as the percentage of agmatine in the culture medium related to the total agmatine, i.e., agmatine in the culture medium plus the residual agmatine in the bacteria. In the case of Bacteroides fragilis and Bacteroides thetaiotaomicron, the apparent rate of efflux amounted to 60 -70%, but it was more than 95% in the case of all other strains of bacteria. These apparent rates represent the percentage of the agmatine produced by the bacteria that would be available for absorption from the gut.
Agmatine synthesis and metabolism in patients with liver cirrhosis. Agmatine was detected in the portal and hepatic venous blood of the patients at median concentrations of 2.4 ng/ml plasma and 2.9 ng/ml plasma, respectively (ranges: 0 -221.5 ng/ml plasma and 0 -12.5 ng/ml plasma, respectively; n ϭ 30 each; Fig. 3A ). There was no significant negative or positive correlation between agmatine concentrations in portal and hepatic venous blood plasma in the individual patients when all patients were analyzed (Spearman correlation coefficient r ϭ Ϫ0.16, P ϭ 0.40). An increase in agmatine concentration in the blood occurred approximately as often and to a similar degree as a decrease in agmatine concentration (Fig. 3) . Subgroup analysis according to the severity of liver cirrhosis as indicated by the Child-Pugh score also failed to reveal significant correlations between agmatine concentrations in portal and hepatic venous blood plasma (Fig. 3B) .
However, for the six portal venous blood samples with plasma agmatine levels above 14 ng/ml [ Fig. 3 ; range: 14.3 to 221.5 ng/ml, which significantly exceeded the portal venous values of the other 24 patients (all below 10 ng/ml)], a distinctly lower agmatine concentration was determined in Fig. 2 . Expression of arginine decarboxylase (ADC), ornithine decarboxylase (ODC), diamine oxidase (DAO), and agmatinase (AGMAT) at the mRNA level in neoplastic colon tissue compared with the adjacent normal colon tissue; mRNA levels were determined by quantitative RT-PCR. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 (unpaired t-test; n ϭ 10 for each enzyme). hepatic venous blood plasma, yielding a significant negative correlation of the portal and hepatic venous plasma concentrations (correlation coefficient r ϭ Ϫ0.67, P Ͻ 0.05); all six hepatic venous agmatine concentrations were far below 10 ng/ml. Thus removal of agmatine during passage of the blood through the liver regularly occurred in these patients.
DISCUSSION
The present study aimed at analyzing regulatory mechanisms underlying agmatine homeostasis in pathophysiology and physiology. The first aspect investigated was based on data from in vitro and in vivo studies, which suggested an association of a distortion of intracellular agmatine homeostasis with neoplastic transformation and tumor growth (2, 18, 25) . Since a modification in the quantitative pattern of agmatine-synthesizing and -metabolizing enzymes (Fig. 1) may play a crucial role in the pathophysiology of such a disorder, we searched for changes in the expression of these enzymes in neoplastic colon cancer tissue compared with adjacent macroscopically normal tissue. The present study is the first one to show that the expression of mRNA encoding the key agmatine forming enzyme arginine decarboxylase was 75% lower in the neoplastic specimens of the colon than in the adjacent tissue. This observation is compatible with the suggestion that the reduced expression of this enzyme is the most important reason for the reduced agmatine content, which was previously determined in neoplastic colon cancer tissue (18) . At the mRNA level, the agmatine-forming enzyme arginine decarboxylase was not genetically altered in the cancer tissue, ruling out the possibility that mutations of arginine decarboxylase are causally involved in the lowered agmatine content and neoplastic transformation. Although it cannot be completely excluded that a reduced function of the agmatine transporter might have contributed to the reduced agmatine content in the neoplastic tissue, this possibility seems to be unlikely because, in previous investigations, we observed no major differences in uptake rates between tumor cell lines and nontumor cell lines (6) .
Expression of the mRNA encoding the agmatine-degrading enzyme diamine oxidase (Fig. 1) was also studied. It was found to be reduced by 50% (Fig. 2) . A possible interpretation is that this reduction reflects the attempt of the cell to counterbalance the reduced formation of agmatine. If this interpretation also held true for other agmatine-degrading enzymes, their expression may also be decreased, as previously shown for agmatinase in a cell line of renal carcinoma cells (3). However, in the colon tumor tissues analyzed in the present study, agmatinase expression was not changed (Fig. 2) , suggesting that this enzyme may be of minor importance for agmatine homeostasis in colon. In agreement with such an assumption, the expression of agmatinase is high in the kidney and liver but very low in the colon (9, 13) .
The expression of the key enzyme in the polyamine synthesis pathway, ornithine decarboxylase ( Fig. 1; for review, see Ref. 20) was markedly increased in the colon carcinoma tissue investigated in the present study. This observation is in agreement with the results of previous studies demonstrating that ornithine decarboxylase mRNA expression (8) and activity (11, 24) are increased in adenocarcinoma tissues compared with normal tissues. The increases in expression and activity of ornithine decarboxylase lead to increased polyamine levels in the cells followed by tumor cell proliferation.
Taken together, the present results in conjunction with previous ones reported in the literature (see also Introduction) support the view that agmatine plays a crucial role in the pathophysiology of tumor cell proliferation in humans. In the present paper, the expression of the key agmatine-forming enzyme, arginine decarboxylase, and of the key polyaminesynthesizing enzyme, ornithine decarboxylase, in colon cancer tissue was compared with the expression of the corresponding enzymes in the normal tissue adjacent to the malignant tumor. In view of these changes in enzyme expression, it may be concluded that intracellular agmatine homeostasis is impaired: agmatine content is reduced, leading to enhanced tumor cell proliferation mediated by the elevated intracellular polyamine content resulting from the increased availability of ornithine decarboxylase. Thus agmatine, by acting as a functional antagonist of polyamines, is involved in the regulation of tumor cell proliferation and growth. It is conceivable that agmatine, in addition to this pathophysiological regulatory mechanism, may also play a role in the control of "normal cell" proliferation.
In the context of absorption of agmatine from the gut, a second important aspect contributing to agmatine homeostasis in humans, namely the availability of bacteria-derived agmatine in the gut lumen, has been subject of the present study. In fact, agmatine formed by the resident intestinal microflora is a major physiological source of the compound in the mammalian organism including humans. To get an idea about the availability of agmatine from this source, the production of agmatine by ten typical representatives of the human intestinal microflora and the efflux of this agmatine into the surrounding culture medium (in analogy to the chyme in the case of the gut) were determined. As a result, it was demonstrated here for the first time that intestinal bacteria species largely differ in their ability to form agmatine (Table 1) . Actinobacterium Eggerthella lenta even failed to reproducibly form any agmatine. Accordingly, a predominance of bacteria species that produce only low amounts of agmatine may cause a reduced availability of agmatine in the chyme for its absorption into the organism and its cells. Such a low agmatine concentration in the chyme may aggravate the above-mentioned tumor-promoting effect of the low cellular agmatine content because of the low arginine decarboxylase expression in tumor cells. As a note of caution, it has to be reminded that the growth conditions in vitro are very different from the environment within the human intestine. Thus the ability of the strains investigated to produce agmatine in the gut lumen could differ significantly from their production in vitro.
The third regulatory mechanism influencing agmatine homeostasis in humans investigated here refers to hepatic elimination of the agmatine absorbed from the gut lumen and to hepatic formation. For ethical reasons, such an investigation could not be carried out in healthy individuals, but simultaneous withdrawal of blood from the portal and hepatic veins as a basis for such a study became possible in patients with liver cirrhosis who underwent therapeutic implantation of an intrahepatic portosystemic stent shunt. In these patients with liver cirrhosis, it was an open question whether the remaining hepatic function is sufficient to modify the level of agmatine in the blood plasma during its passage through the liver. Since, in fact, blood samples were always taken from the portal and hepatic veins at the same time, possible periodic changes in absorption cannot account for differences of agmatine levels between the corresponding blood samples. In the blood of all patients, agmatine could be detected at concentrations similar to those previously reported for humans (5, 28) . The agmatine levels found in the patients were also comparable to those in rat blood determined in our laboratory with the same methods (means Ϯ SE: 0.97 Ϯ 0.23 ng/ml plasma; n ϭ 38).
Due to the high amount of agmatine synthesized by bacteria in, and absorbed from, the gut lumen, loss of agmatine in blood was expected to occur as a result and indicator of its predominant metabolism during passage through the liver. However, the agmatine levels in portal and hepatic venous blood plasma were, when considering all cases, not negatively correlated. This held true irrespective of the degree of impairment of liver function by the cirrhosis as indicated by the Child-Pugh scores (Fig. 3, A and B) . To provide an explanation for this phenomenon, it must be taken into account that the hepatocyte not only metabolizes agmatine but is also capable of synthesizing this compound (7, 29) . Obviously, at low agmatine concentrations in the portal venous blood plasma, agmatine synthesis can dominate over its metabolism, reflected by the increase in agmatine concentration during passage through the liver. In the patients investigated here, such increases of agmatine level in hepatic venous blood plasma over the value in portal venous blood plasma occurred approximately as often as the reverse process, i.e., metabolization.
However, it should be noted that a significant negative correlation of agmatine levels in portal and hepatic venous blood plasma was observed for the subgroup of six patients who had markedly higher agmatine levels in their portal venous blood plasma (Ͼ14 ng/ml) than the other 24 patients (Ͻ 10 ng/ml; Fig. 3) . In those six patients, agmatine metabolism clearly predominated over synthesis, leading to a loss of agmatine in blood during passage through the liver. Thus the agmatine level in hepatic venous blood plasma was adjusted by the liver to the same range as in the corresponding blood samples from the other patients.
Concluding remarks. Important physiological and pathophysiological regulatory mechanisms underlying agmatine homeostasis and its disorders, respectively, have been disclosed in the present study in humans. Thus an impairment of agmatine homeostasis has been proven to be involved in the regulation of malignant cell proliferation. Our data demonstrate for the first time that the expression of arginine decarboxylase, the key enzyme for the biosynthesis of agmatine, is reduced in neoplastic tissues in humans. It appears probable that agmatine, in addition to this pathophysiological relevance, may also be involved in the physiological control of normal cell proliferation and growth. The amount of agmatine formed by the resident intestinal microflora is an important physiological source of agmatine in the human organism. The various species of intestinal bacteria largely differ in their ability to form agmatine. Accordingly, the amount of agmatine available for absorption should differ considerably depending on the composition of the bacterial flora in the chyme. Predominance of bacteria producing only low amounts of agmatine available for absorption from the gut lumen may lead to an increase in the tumor cell proliferation-promoting effect associated with the decreased expression of arginine decarboxylase (see above). Finally, evidence has been presented that the liver plays a crucial physiological role in the maintenance of agmatine homeostasis in the human organism by its ability to take up and metabolize agmatine on the one hand and synthesize it on the other. Even the impaired liver function in patients with liver cirrhosis is sufficient to adjust agmatine concentrations in the hepatic venous blood plasma. This occurs irrespective of the degree of functional impairment of the cirrhotic liver, as defined by the different Child-Pugh score. Accordingly, a rather constant supply of all tissues of the organism with agmatine for cellular uptake is made possible.
